-
EP1526866
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1526866
| EP1526866 - DRUG CONJUGATE COMPRISING AN ERYTHROPOIETIN RECEPTOR LIGAND AND AN ANTICANCER AGENT [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 30.04.2010 Database last updated on 08.06.2024 | Most recent event Tooltip | 30.04.2010 | Application deemed to be withdrawn | published on 02.06.2010 [2010/22] | Applicant(s) | For all designated states The Queen's University of Belfast University Road Belfast BT7 1NN Northern Ireland / GB | [N/P] |
| Former [2005/18] | For all designated states The Queen's University of Belfast University Road Belfast BT7 1NN, Northern Ireland / GB | Inventor(s) | 01 /
LAPPIN, Terence 6 Downshire Park Hillsborough, BT25 6HB / GB | 02 /
MANN, John 6 Ardmore Terrace Holywood BT18 9BH / GB | 03 /
MCMANUS, Michael 16 Aranmore Avenue Black Rock, Victoria 3193 / AU | 04 /
MAXWELL, perry, INSTITUTE OF pATHOLOGY Queens University Belfast, Royal Group of Hospitals Trust, Belfast, BT12 6BA / GB | [2005/28] |
| Former [2005/18] | 01 /
LAPPIN, Terence 6 Downshire Park Hillsborough, BT25 6HB / GB | ||
| 02 /
MANN, John 6 Ardmore Terrace Holywood BT18 9BH / GB | |||
| 03 /
MCMANUS, Michael 16 Aranmore Avenue Black Rock, Victoria 3193 / AU | Representative(s) | Main, Malcolm Charles, et al Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow G5 8PL / GB | [N/P] |
| Former [2005/18] | Main, Malcolm Charles, et al Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow G5 8PL / GB | Application number, filing date | 03738226.4 | 21.05.2003 | [2005/18] | WO2003GB02194 | Priority number, date | GB20020011578 | 21.05.2002 Original published format: GB 0211578 | [2005/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO03097106 | Date: | 27.11.2003 | Language: | EN | [2003/48] | Type: | A2 Application without search report | No.: | EP1526866 | Date: | 04.05.2005 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.11.2003 takes the place of the publication of the European patent application. | [2005/18] | Search report(s) | International search report - published on: | EP | 12.02.2004 | Classification | IPC: | A61K38/18 | [2005/18] | CPC: |
A61K38/1816 (EP,US);
A61K47/64 (EP,US)
| C-Set: |
A61K38/1816, A61K2300/00 (EP,US)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/18] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | ERYTHROPOIETIN REZEPTOR LIGANDEN UND ANTIKREBSMITTEL ENTHALTENDES ARZNEIMITTEL KONJUGAT | [2005/18] | English: | DRUG CONJUGATE COMPRISING AN ERYTHROPOIETIN RECEPTOR LIGAND AND AN ANTICANCER AGENT | [2005/18] | French: | CONJUGUE MEDICAMENTEUX COMPRENANT UN LIGAND POUR LE RECEPTOR D'ERYTROPOIETINE ET UN AGENT ANTICANCEREUX | [2005/18] | Entry into regional phase | 18.11.2004 | National basic fee paid | 18.11.2004 | Designation fee(s) paid | 18.11.2004 | Examination fee paid | Examination procedure | 18.11.2004 | Examination requested [2005/18] | 27.08.2009 | Despatch of a communication from the examining division (Time limit: M04) | 01.12.2009 | Application deemed to be withdrawn, date of legal effect [2010/22] | 14.01.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2010/22] | Fees paid | Renewal fee | 13.05.2005 | Renewal fee patent year 03 | 20.04.2006 | Renewal fee patent year 04 | 07.05.2007 | Renewal fee patent year 05 | 28.03.2008 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 31.05.2009 | 07 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO0067769 (ORTHO MCNEIL PHARM INC [US]) [X] 1-18 * the whole document *; | [X]WO9810650 (UNIV EAST CAROLINA [US], et al) [X] 1-18 * the whole document *; | [X]WO0061164 (KENNETH S WARREN LAB [US]) [X] 1-18 * the whole document *; | [X]US6221608 (MIDDLETON STEVEN A [US], et al) [X] 10-12,15 * the whole document *; | [Y] - KRATZ F ET AL, "Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19970304), vol. 7, no. 5, ISSN 0960-894X, pages 617 - 622, XP004136076 [Y] 1-8,13 * the whole document * DOI: http://dx.doi.org/10.1016/S0960-894X(97)00069-3 | [Y] - ROODMAN G D ET AL, "DNA polymerase activities during erythropoiesis. Effects of erythropietin, vinblastine, colcemid, and daunomycin.", EXPERIMENTAL CELL RESEARCH. UNITED STATES 15 MAR 1975, (19750315), vol. 91, no. 2, ISSN 0014-4827, pages 269 - 278, XP009015632 [Y] 1-8,13 * the whole document * DOI: http://dx.doi.org/10.1016/0014-4827(75)90104-4 |